1. Pink Sheet

Keeping Track Of Good News For AstraZeneca, Pfizer, Promius, And Sunovion

 
• By Bridget Silverman

NDA and BLA submission news from our US FDA Performance Tracker.

Keeping Track Feature image

Two novel oncologics joined the September user fee calendar at the US FDA this week: an antibody-immunotoxin conjugate from AstraZeneca PLC for a rare, slow-growing leukemia and an epidermal growth factor receptor (EGFR)-directed therapy from Pfizer Inc. Both are receiving priority review.

Promius Pharma LLC and Sunovion Pharmaceuticals Inc

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Product Reviews

More from Pink Sheet

EU Shaping Biotech Act To Unleash SME Potential

 
• By Neena Brizmohun

European companies, in particular small and midsize enterprises, spin-offs and start-ups have a hard time expanding within the single market “because of a complex regulatory framework that is perceived as slow and burdensome,” according to the European Commission.

New EU Filings

 
• By Neena Brizmohun

Brensocatib, Insmed's investigational treatment for non-cystic fibrosis bronchiectasis, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.

‘Tectonic’ Arkansas PBM Legislation May Upend Industry

 
• By Tim Casey

Industry will fight hard to prevent other states or the federal government from adopting measures similar to Arkansas' law preventing PBMs from owning pharmacies.